Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005047 · ClinicalTrials.gov registry record · Phase 3
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 521
- Enrollment target
NCT00005047 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 521 participants.
The verdict
NCT00005047, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 521 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective than observation alone in treating bladder cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy to see how well it works compared to observation alone in treating patients with bladder cancer.
Interventions
- DRUG cisplatin
- DRUG methotrexate
- DRUG vinblastine
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 521 participants |
| Start Date | 1997-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005047
The ClinicalTrials.gov registry entry for NCT00005047 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 521 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00005047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005047 about?
NCT00005047 is a clinical study titled "4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective than observation alone in treating bladder cancer. P...
What is the current status of trial NCT00005047?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 521 participants. The study started on 1997-08. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00005047?
The interventions under investigation include: cisplatin (DRUG), methotrexate (DRUG), vinblastine (DRUG), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005047?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.